Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Autor: Joseph P. Casazza, Amelia R. Hofstetter, Pamela J. M. Costner, LaSonji A. Holman, Cynthia S. Hendel, Alicia T. Widge, Richard L. Wu, William R. Whalen, Jennifer Cunningham, Anita Arthur, Xiaolin Wang, Abidemi Ola, Jamie Saunders, Floreliz Mendoza, Laura Novik, Maria C. Burgos Florez, Ana M. Ortega-Villa, Preeti J. Apte, Larisa Strom, Lu Wang, Marjaan Imam, Manjula Basappa, Mursal Naisan, Mike Castro, Jessica F. Trost, Sandeep R. Narpala, Hillary A. Vanderven, Galina V. Yamshchikov, Nina M. Berkowitz, Ingelise J. Gordon, Sarah H. Plummer, Diane L. Wycuff, Sandra Vazquez, Rebecca A. Gillespie, Adrian Creanga, William C. Adams, Kevin Carlton, Jason G. Gall, Adrian B. McDermott, Leonid A. Serebryannyy, Katherine V. Houser, Richard A. Koup, Barney S. Graham, Julie E. Ledgerwood, John R. Mascola, Theodore C. Pierson, Sarah F. Andrews, Masaru Kanekiyo, Lesia K. Dropulic, The VRC 323 study team

Publikováno v: npj Vaccines, Vol 9, Iss 1, Pp 1-10 (2024)

Abstract The relative conservation of the influenza hemagglutinin (HA) stem compared to that of the immunodominant HA head makes the HA stem an attractive target for broadly protective influenza vaccines. Here we report the first-in-human, dose-escal

Externí odkaz: https://doaj.org/article/96bea20f4a6e46d8a78a3f7c6943f262

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

Autor: Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan, Myra Happe, Larisa Strom, Nina M Berkowitz, Mercy Guech, Zonghui Hu, Mike Castro, Manjula Basappa, Lu Wang, Kwang Low, LaSonji A Holman, Floreliz Mendoza, Ingelise J Gordon, Sarah H Plummer, Olga Trofymenko, Kathleen S Strauss, Sudhaunshu Joshi, Biraj Shrestha, Matthew Adams, Andrezza Campos Chagas, Jittawadee R Murphy, Judy Stein, Somia Hickman, Andrew McDougal, Bob Lin, Sandeep R Narpala, Sandra Vazquez, Leonid Serebryannyy, Adrian McDermott, Martin R Gaudinski, Edmund V Capparelli, Emily E Coates, Richard L Wu, Julie E Ledgerwood, Lesia K Dropulic, Robert A Seder, Cheryl Young, Colleen Boyce, Jennifer Winkler, Susan Holian, Nancy Greenberg, Shirley George, Alyson Kwon, Brenda Dorsey, Ana Raquel Da Costa, William Witt, Daryl Grays, Arren Gapasin, Paula Bernal, Jeffrey Floyd, Eric Goldstein, Leslie Howe, Myounghee Lee, Jennifer Marron, Kelly Brooks, Lisa Turek, Patricia Farley, Shantel Frels, Delores Booth, Jason Gall, Kevin Carlton, Gabriela Albright, Nadia Amharref, Kandace Atallah, Sashikanth Banappagari, Niutish Bastani, Daniel Blackstock, Bobby Boonyaratanakornkit, Elizabeth Carey, Adam Charlton, Rajoshi Chaudhuri, Alegria M. Caringal, Mingzhong Chen, Peifeng Chen, Wei Cheng, Daniel Gowetski, Krishana Gulla, Erica Hastings, Joe Horwitz, Vera Ivleva, Dan Kordella, Lisa A. Kueltzo, Sara Lagler, Matt Le, James Lee, Paula Lei, Yile Li, Attila Nagy, Aakash Patel, Peyi Runsewe, Will Shadrick, Shamitha Shetty, Hairong Wang, Calvin Webber, Farah Vejzagic, Yoo-Jung Yang

Publikováno v: The Lancet Infectious Diseases. 23:578-588

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f600caf7a91af2dc3f76ba29b4af090
https://doi.org/10.1016/s1473-3099(22)00793-9

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Autor: Peifeng Chen, Anita Arthur, Kaitlyn M. Morabito, Kristin Leach, Xiaolin Wang, Grace L. Chen, Attila Nagy, Lauren A. Chang, Jon Cooper, Amy L. Chamberlain, Janel Holland-Linn, Olga Vasilenko, Alicia T. Widge, Shufeng Bai, Judith A Stein, LaSonji A. Holman, Cristina Carter, Iris Pittman, Deepika Gollapudi, Lisa A. Kueltzo, Colleen Fridley, Michelle C. Crank, Amritha Menon, William Whalen, Mridul Ghosh, Cynthia S. Hendel, Martha Nason, Amy Liu, Althaf Hussain, Laura Novik, Pernell Williams, Maria Burgos Florez, Robert T. Bailer, Thuy Nguyen, Brenda Larkin, Tracy J. Ruckwardt, Pamela Costner, Lam Le, Zhong Zhao, Elizabeth Carey, Vera Ivleva, Jennifer Walters, John R. Mascola, Jennifer Cunningham, Olga Trofymenko, Ya-chen Chang, Somia P. Hickman, Martin R. Gaudinski, Richard M. Schwartz, Slobodanka D. Manceva, Kevin Carlton, Barney S. Graham, Rahul Ragunathan, Jason G. D. Gall, Ana M. Ortega-Villa, Colin Tran, Sarah H. Plummer, Abidemi Ola, Ro Shauna S Rothwell, Ingelise J. Gordon, Mingzhong Chen, Jamie G. Saunders, Aba Mensima Eshun, Bob C. Lin, Azad Kumar, Nina M. Berkowitz, Xun Liu, Cora Trelles Cartagena, Emily Phung, Galina Yamshchikov, Joe Horwitz, Sarah O’Connell, Florence Kaltovich, Floreliz Mendoza, LaShawn Requilman, Man Chen, Preeti Apte, Christopher Lee, Renunda Hicks

Publikováno v: Lancet Respir Med

Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sust

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81ae60b574c97c5be6e3eabd0b1e70f3
https://doi.org/10.1016/s2213-2600(21)00098-9

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

Autor: Amarendra, Pegu, Sarah E, O'Connell, Stephen D, Schmidt, Sijy, O'Dell, Chloe A, Talana, Lilin, Lai, Jim, Albert, Evan, Anderson, Hamilton, Bennett, Kizzmekia S, Corbett, Britta, Flach, Lisa, Jackson, Brett, Leav, Julie E, Ledgerwood, Catherine J, Luke, Mat, Makowski, Martha C, Nason, Paul C, Roberts, Mario, Roederer, Paulina A, Rebolledo, Christina A, Rostad, Nadine G, Rouphael, Wei, Shi, Lingshu, Wang, Alicia T, Widge, Eun Sung, Yang, John H, Beigel, Barney S, Graham, John R, Mascola, Mehul S, Suthar, Adrian B, McDermott, Nicole A, Doria-Rose, Jae, Arega, Wendy, Buchanan, Mohammed, Elsafy, Binh, Hoang, Rebecca, Lampley, Aparna, Kolhekar, Hyung, Koo, Catherine, Luke, Mamodikoe, Makhene, Seema, Nayak, Rhonda, Pikaart-Tautges, Janie, Russell, Elisa, Sindall, Pratap, Kunwar, Evan J, Anderson, Amer, Bechnak, Mary, Bower, Andres F, Camacho-Gonzalez, Matthew, Collins, Ana, Drobeniuc, Venkata Viswanadh, Edara, Srilatha, Edupuganti, Katharine, Floyd, Theda, Gibson, Cassie M Grimsley, Ackerley, Brandi, Johnson, Satoshi, Kamidani, Carol, Kao, Colleen, Kelley, Hollie, Macenczak, Michele Paine, McCullough, Etza, Peters, Varun K, Phadke, Nadine, Rouphael, Erin, Scherer, Amy, Sherman, Kathy, Stephens, Mehgan, Teherani, Jessica, Traenkner, Juton, Winston, Inci, Yildirim, Lee, Barr, Joyce, Benoit, Barbara, Carste, Joe, Choe, Maya, Dunstan, Roxanne, Erolin, Jana, Ffitch, Colin, Fields, Lisa A, Jackson, Erika, Kiniry, Susan, Lasicka, Stella, Lee, Matthew, Nguyen, Stephanie, Pimienta, Janice, Suyehira, Michael, Witte, Nedim Emil, Altaras, Andrea, Carfi, Marjorie, Hurley, Rolando, Pajon, Wellington, Sun, Tal, Zaks, Rhea N, Coler, Sasha E, Larsen, Kathleen M, Neuzil, Lisa C, Lindesmith, David R, Martinez, Jennifer, Munt, Michael, Mallory, Caitlin, Edwards, Ralph S, Baric, Nina M, Berkowitz, Eli A, Boritz, Kevin, Carlton, Pamela, Costner, Adrian, Creanga, Daniel C, Douek, Martin, Gaudinski, Ingelise, Gordon, LaSonji, Holman, Kwanyee, Leung, Bob C, Lin, Mark K, Louder, Kaitlyn M, Morabito, Laura, Novik, Sarah, O'Connell, Marcelino, Padilla, Phillip A, Swanson, Yi, Zhang, James D, Chappell, Mark R, Denison, Tia, Hughes, Xiaotao, Lu, Andrea J, Pruijssers, Laura J, Stevens, Christine M, Posavad, Michael, Gale, Vineet, Menachery, Pei-Yong, Shi

Publikováno v: bioRxiv
article-version (status) pre
article-version (number) 1

SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, and the durability of such responses has not been previously reported. Here, we present a comprehensive assessment of the impact of variants B.1.1.7, B.1.351, P.1, B.1.429

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e783dd6f4280d48257f617acf459420
https://pubmed.ncbi.nlm.nih.gov/34385356

Molecular Dissection Of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination

Autor: Scott A. Rush, Pamela Costner, John R. Mascola, Morgan S.A. Gilman, Yi Zhang, Samuel Darko, Barney S. Graham, Chaim A. Schramm, Alexandrine Derrien-Colemyn, John Misasi, Guillaume Stewart-Jones, Bharat Madan, Peter D. Kwong, Martin R. Gaudinski, Chen-Hsiang Shen, Grace L. Chen, Kaitlyn M. Morabito, Amy Ransier, Jason S. McLellan, Michelle C. Crank, Larissa Ault, Tracy J. Ruckwardt, LaSonji A. Holman, Daniel C. Douek, Sarah A.M. Lucas, Emily Phung, Nina M. Berkowitz, Brandon J. DeKosky, Nicole A. Doria-Rose, Nancy J. Sullivan, Daniel Wrapp, Maryam Mukhamedova, Lingshu Wang, Lauren A. Chang, Somia P. Hickman

Publikováno v: SSRN Electronic Journal.

An effective vaccine for RSV is an unrealized public health goal. Recently, a single dose of the prefusion-stabilized fusion (F) glycoprotein subunit vaccine (DS-Cav1) was shown to substantially increase serum neutralizing activity in healthy adults.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a753eb36429a1136c8b6be4ec661c83
https://doi.org/10.2139/ssrn.3712702